當前位置：首頁 SCI期刊 SCIE期刊醫學中科院3區 JCRQ3 期刊介紹(非官網)

European Journal Of Clinical PharmacologySCIE

國際簡稱：EUR J CLIN PHARMACOL 參考譯名：歐洲臨床藥理學雜志

中科院分區
3區
CiteScore分區
Q2
JCR分區
Q3

基本信息：: ISSN：0031-6970; E-ISSN：1432-1041; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區：GERMANY; 出版商：Springer Berlin Heidelberg; 出版語言：English; 出版周期：Monthly; 出版年份：1968; 研究方向：醫學-藥學

評價信息：: 影響因子：2.4; H-index：99; CiteScore指數：5.4; SJR指數：0.727; SNIP指數：0.99

發文數據：: Gold OA文章占比：32.62%; 研究類文章占比：70.59%; 年發文量：153; 自引率：0.0344...; 開源占比：0.3214; 出版撤稿占比：0; 出版國人文章占比：0.07; OA被引用占比：0.2584...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介European Journal Of Clinical Pharmacology期刊介紹

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

-a compound that is interesting and new in some basic or fundamental way, or

-methods that are original in some basic sense, or

-a highly unexpected outcome, or

-conclusions that are scientifically novel in some basic or fundamental sense.

期刊簡介European Journal Of Clinical Pharmacology期刊介紹

《European Journal Of Clinical Pharmacology》自1968出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：一般,3-8周
醫學
PHARMACOLOGY & PHARMACY
SCIE
中科院3區
非預警

Cite Score數據（2024年最新版）European Journal Of Clinical Pharmacology Cite Score數據

CiteScore：5.4
SJR：0.727
SNIP：0.99

學科類別	分區	排名	百分位
大類：Medicine 小類：Pharmacology (medical)	Q2	92 / 272	66%
大類：Medicine 小類：Pharmacology	Q2	142 / 313	54%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區European Journal Of Clinical Pharmacology 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	3區	PHARMACOLOGY & PHARMACY 藥學	3區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區European Journal Of Clinical Pharmacology JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：PHARMACOLOGY & PHARMACY	SCIE	Q3	188 / 354	47%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：PHARMACOLOGY & PHARMACY	SCIE	Q3	192 / 354	45.9%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
France103
Spain94
CHINA MAINLAND93
Netherlands86
GERMANY (FED REP GER)77
USA77
Sweden76
Italy56
Japan56
England48

本刊中國學者近年發表論文

1、The pharmacokinetics and safety of lidocaine in liver cancer patients undergoing hepatic resection
Author: He, Chaoqun; Jin, Ying; Zhang, Yang; Zhang, Mengyu; Di, Xiangjie; Fu, Lisha; Qi, Xiaohui; Liu, Runhan; Zheng, Li; Wang, Zhenlei; Li, Jingdong; Tu, Faping

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s00228-023-03498-0
2、Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis
Author: Ma, Shaodi; Qu, Guangbo; Sun, Chenyu; Liu, Haixia; Jiang, Yuemeng; Li, Ning; Wu, Birong; Gao, Juan; Feng, Linya; Xie, Peng; Xia, Weihang; Kim, Na Hyun; Lowe, Scott; Bentley, Rachel; Zhu, Yike; Zhou, Qin; Sun, Yehuan

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 39-61. DOI: 10.1007/s00228-022-03414-y
3、Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis
Author: Hou, Xiaowen; Cen, Kaiwen; Cui, Ying; Zhang, Yuhong; Feng, Xu

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 63-70. DOI: 10.1007/s00228-022-03413-z
4、The risk of congenital heart defects associated with corticosteroids use during the first trimester of pregnancy: a systematic review and meta-analysis
Author: Wei, Jiehua; Xia, Fan; Miao, Junxiang; Wang, Tingting; Chen, Lizhang; Yan, Xuemei

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 1-11. DOI: 10.1007/s00228-022-03416-w
5、A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure
Author: Liao, Ru; Dong, Yalin; Chen, Lihong; Wang, Taotao; Li, Houli; Dong, Haiyan

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 1, pp. 149-157. DOI: 10.1007/s00228-022-03427-7
6、Reliability and feasibility of home-based dried blood spot in therapeutic drug monitoring: a systematic review and meta-analysis
Author: Xiaoyong, Xu; Xilin, Ge; Guangfei, Wang; Wei, Wu; Xiaowen, Zhai; Hong, Xu; Huimin, Zhang; Zhiping, Li

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 2, pp. 183-193. DOI: 10.1007/s00228-022-03417-9
7、Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials
Author: Sun, Yingchao; Yue, Lei; Hu, Weiling

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 2, pp. 279-288. DOI: 10.1007/s00228-022-03430-y
8、Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis
Author: Li, Xujia; Huang, Jinsheng; Jiang, Chang; Chen, Ping; Quan, Qi; Jiang, Qi; Li, Shengping; Guo, Guifang

Journal: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023; Vol. 79, Issue 3, pp. 323-340. DOI: 10.1007/s00228-022-03441-9